Lira Macarena Gomez, Provezza Lisa, Malerba Giovanni, Naldi Luigi, Remuzzi Giuseppe, Boschiero Luigino, Forni Alberto, Rugiu Carlo, Piaserico Stefano, Alaibac Mauro, Turco Alberto, Girolomoni Giampiero, Tessari Gianpaolo
Section of Biology and Genetics, University of Verona, Verona, Italy.
Exp Dermatol. 2006 Dec;15(12):958-65. doi: 10.1111/j.1600-0625.2006.00500.x.
Solid organ transplant recipients are at higher risk of non-melanoma skin cancer (NMSC), especially basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Genetic alterations in the production of detoxifying enzymes such as glutathione S-transferase (GST) and CYP1A1 may enhance this risk. We investigated the frequency of GST genotypes (GSTM1, GSTM3, GSTT1 and GSTP1) and CYP1A1 in 239 transplant recipients: 107 cases with NMSC and 132 controls free from NMSC matched for type of transplanted organ, duration of transplantation, sex and age. Allele GSTP1*A was associated with a higher risk of NMSC [odds ratio (OR) 1.7 (1.1-2.5); P = 0.017]. Homozygosity for allele GSTP1 Val(105) was lower in cases [OR 0.3 (0.1-0.8); P = 0.012], especially in patients with SCC [OR 0.1 (0.0-0.7); P = 0.012]. A higher risk of BCC was found in patients with GSTM1 null/null [null/null versus A + B, OR 3.1 (1.4-6.8); P = 0.003]. Analysis of allelism and interaction between allelic variants showed significant association between combined GSTM1 and CYP1A1 Val(462) genotypes, where individuals homozygous for the risk allele GSTM1 null and carrying also the allele CYP1A1 Val(462), show a higher risk of developing NMSC [OR 4.5 (1.1-21.4); P = 0.03], especially SCC [OR 6.5 (1.4-34.4); P = 0.01]. GSTP1 polymorphisms are associated with both BCC and SCC risk. GSTM1 polymorphisms seem to be involved in BCC risk, while GSTM1 null/null genotype combined with CYP1A1 allele Val(462) are associated with a higher risk for SCC, indicating that allelism and/or interactions between allelic variants at other loci may also influence the risk of NMSC, particularly SCC.
实体器官移植受者患非黑色素瘤皮肤癌(NMSC)的风险更高,尤其是基底细胞癌(BCC)和鳞状细胞癌(SCC)。解毒酶如谷胱甘肽S-转移酶(GST)和CYP1A1产生过程中的基因改变可能会增加这种风险。我们调查了239名移植受者中GST基因型(GSTM1、GSTM3、GSTT1和GSTP1)和CYP1A1的频率:107例NMSC患者和132名无NMSC的对照者,后者在移植器官类型、移植持续时间、性别和年龄方面进行了匹配。等位基因GSTP1*A与NMSC风险较高相关[比值比(OR)1.7(1.1 - 2.5);P = 0.017]。病例中GSTP1 Val(105)等位基因的纯合性较低[OR 0.3(0.1 - 0.8);P = 0.012],尤其是在SCC患者中[OR 0.1(0.0 - 0.7);P = 0.012]。GSTM1 null/null患者患BCC的风险较高[null/null与A + B相比,OR 3.1(1.4 - 6.8);P = 0.003]。对等位基因及等位基因变体之间相互作用的分析显示,GSTM1和CYP1A1 Val(462)基因型组合之间存在显著关联,即携带风险等位基因GSTM1 null纯合且同时携带CYP1A1 Val(462)等位基因的个体,发生NMSC的风险更高[OR 4.5(1.1 - 21.4);P = 0.03],尤其是SCC[OR 6.5(1.4 - 34.4);P = 0.01]。GSTP1多态性与BCC和SCC风险均相关。GSTM1多态性似乎与BCC风险有关,而GSTM1 null/null基因型与CYP1A1等位基因Val(462)组合与SCC风险较高相关,这表明其他位点等位基因变体之间的等位基因及/或相互作用也可能影响NMSC的风险,尤其是SCC。